|
1
|
Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS,
Cheng AL, Chen PJ and Chen KF: Mcl-1-dependent activation of Beclin
1 mediates autophagic cell death induced by sorafenib and SC-59 in
hepatocellular carcinoma cells. Cell Death Dis. 4:e4852013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li W, Huang X, Tong H, Wang Y, Zhang T,
Wang W, Dai L, Li T, Lin S and Wu H: Comparison of the regulation
of β-catenin signaling by type I, type II and type III interferons
in hepatocellular carcinoma cells. PLoS One. 7:e470402012.
|
|
3
|
Liao J, Xu T, Zheng JX, Lin JM, Cai QY, Yu
DB and Peng J: Nitidine chloride inhibits hepatocellular carcinoma
cell growth in vivo through the suppression of the
JAK1/STAT3 signaling pathway. Int J Mol Med. 32:79–84.
2013.PubMed/NCBI
|
|
4
|
Cao M, Cabrera R, Xu Y, Firpi R, Zhu H,
Liu C and Nelson DR: Hepatocellular carcinoma cell supernatants
increase expansion and function of CD4+ CD25+
regulatory T cells. Lab Invest. 87:582–590. 2007.PubMed/NCBI
|
|
5
|
Subramaniam A, Shanmugam MK, Perumal E, Li
F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK, Hui KM
and Sethi G: Potential role of signal transducer and activator of
transcription (STAT)3 signaling pathway in inflammation, survival,
proliferation and invasion of hepatocellular carcinoma. Biochim
Biophys Acta. 1835:46–60. 2013.
|
|
6
|
Lin HY, Chiang CH and Hung WC: STAT3
upregulates miR-92a to inhibit RECK expression and to promote
invasiveness of lung cancer cells. Br J Cancer. 109:731–738. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ren L, Wang X, Dong Z, Liu J and Zhang S:
Bone metastasis from breast cancer involves elevated IL-11
expression and the gp130/STAT3 pathway. Med Oncol. 30:6342013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cho KH, Jeong KJ, Shin SC, Kang J, Park CG
and Lee HY: STAT3 mediates TGF-β1-induced TWIST1 expression and
prostate cancer invasion. Cancer Lett. 336:167–173. 2013.
|
|
9
|
Lesinski GB: The potential for targeting
the STAT3 pathway as a novel therapy for melanoma. Future Oncol.
9:925–927. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Y, Fuchs J, Li C and Lin J: IL-6, a
risk factor for hepatocellular carcinoma: FLLL32 inhibits
IL-6-induced STAT3 phosphorylation in human hepatocellular cancer
cells. Cell Cycle. 9:3423–3427. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schmidt N, Neumann-Haefelin C and Thimme
R: Cellular immune responses to hepatocellular carcinoma: lessons
for immunotherapy. Dig Dis. 30:483–491. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xin H, Zhang C, Herrmann A, Du Y, Figlin R
and Yu H: Sunitinib inhibition of Stat3 induces renal cell
carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Cancer Res. 69:2506–2513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kortylewski M, Kujawski M, Wang T, Wei S,
Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, Jove R,
Pardoll D and Yu H: Inhibiting Stat3 signaling in the hematopoietic
system elicits multicomponent antitumor immunity. Nat Med.
11:1314–1321. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang T, Niu G, Kortylewski M, Burdelya L,
Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola
D, Dalton W, Jove R, Pardoll D and Yu H: Regulation of the innate
and adaptive immune responses by Stat-3 signaling in tumor cells.
Nat Med. 10:48–54. 2004. View
Article : Google Scholar
|
|
15
|
Iorio R, Frisullo G, Nociti V, Patanella
KA, Bianco A, Marti A, Mirabella M, Tonali PA and Batocchi AP:
T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear
cells during pregnancy correlates with post-partum activation of
multiple sclerosis. Clin Immunol. 131:70–83. 2009. View Article : Google Scholar
|
|
16
|
Emmerich J, Mumm JB, Chan IH, LaFace D,
Truong H, McClanahan T, Gorman DM and Oft M: IL-10 directly
activates and expands tumor-resident CD8+ T cells
without de novo infiltration from secondary lymphoid organs. Cancer
Res. 72:3570–3581. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu J and Paul WE: CD4 T cells: fates,
functions, and faults. Blood. 112:1557–1569. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ognjanovic S, Yuan JM, Chaptman AK, Fan Y
and Yu MC: Genetic polymorphisms in the cytokine genes and risk of
hepatocellular carcinoma in low-risk non-Asians of USA.
Carcinogenesis. 30:758–762. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nieters A, Yuan JM, Sun CL, Zhang ZQ,
Stoehlmacher J, Govindarajan S and Yu MC: Effect of cytokine
genotypes on the hepatitis B virus-hepatocellular carcinoma
association. Cancer. 103:740–748. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou D, Gu FM, Gao Q, Li QL, Zhou J and
Miao CH: Effects of anesthetic methods on preserving anti-tumor
T-helper polarization following hepatectomy. World J Gastroenterol.
18:3089–3098. 2012. View Article : Google Scholar
|
|
21
|
Willson TA, Jurickova I, Collins M and
Denson LA: Deletion of intestinal epithelial cell STAT3 promotes
T-lymphocyte STAT3 activation and chronic colitis following acute
dextran sodium sulfate injury in mice. Inflamm Bowel Dis.
19:512–525. 2013. View Article : Google Scholar
|
|
22
|
Lepiller Q, Abbas W, Kumar A, Tripathy MK
and Herbein G: HCMV activates the IL-6-JAK-STAT3 axis in HepG2
cells and primary human hepatocytes. PLoS One. 8:e595912013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Y, Liu A, Li H, Li C and Lin J:
Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced
JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Cancer Prev Res (Phila). 4:1296–1305. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chaudhry A, Samstein RM, Treuting P, Liang
Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Brüning JC, Müller
W and Rudensky AY: Interleukin-10 signaling in regulatory T cells
is required for suppression of Th17 cell-mediated inflammation.
Immunity. 34:566–578. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shin HD, Park BL, Kim LH, Jung JH, Kim JY,
Yoon JH, Kim YJ and Lee HS: Interleukin 10 haplotype associated
with increased risk of hepatocellular carcinoma. Hum Mol Genet.
12:901–906. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nieminen JK, Niemi M, Sipponen T, Salo HM,
Klemetti P, Färkkilä M, Vakkila J and Vaarala O: Dendritic cells
from Crohn’s disease patients show aberrant STAT1 and STAT3
signaling. PLoS One. 8:e707382013.
|
|
27
|
Hsia CY, Huo TI, Chiang SY, Lu MF, Sun CL,
Wu JC, Lee PC, Chi CW, Lui WY and Lee SD: Evaluation of
interleukin-6, interleukin-10 and human hepatocyte growth factor as
tumor markers for hepatocellular carcinoma. Eur J Surg Oncol.
33:208–212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bruix J and Sherman M: Practice Guidelines
Committee, American Association for the Study of Liver Diseases:
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar
|
|
29
|
Li F, Ren W, Zhao Y, Fu Z, Ji Y, Zhu Y and
Qin C: Downregulation of GRIM-19 is associated with hyperactivation
of p-STAT3 in hepatocellular carcinoma. Med Oncol. 29:3046–3054.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bandyopadhyay D, Cruz J, Morales LD, Arman
HD, Cuate E, Lee YS, Banik BK and Kim DJ: A green approach toward
quinoxalines and bis-quinoxalines and their biological evaluation
against A431, human skin cancer cell lines. Future Med Chem.
5:1377–1390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tremblay ML: On the role of tyrosine
phosphatases as negative regulators of STAT signaling in breast
cancers: new findings and future perspectives. Breast Cancer Res.
15:3122013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Garner JM, Fan M, Yang CH, Du Z, Sims M,
Davidoff AM and Pfeffer LM: Constitutive activation of signal
transducer and activator of transcription 3 (STAT3) and nuclear
factor-κB signaling in glioblastoma cancer stem cells regulates the
Notch pathway. J Biol Chem. 288:26167–26176. 2013.
|
|
33
|
Nishimoto A, Kugimiya N, Hosoyama T, Enoki
T, Li TS and Hamano K: JAB1 regulates unphosphorylated STAT3
DNA-binding activity through protein-protein interaction in human
colon cancer cells. Biochem Biophys Res Commun. 438:513–518. 2013.
View Article : Google Scholar
|
|
34
|
Mano Y, Aishima S, Fujita N, Tanaka Y,
Kubo Y, Motomura T, Taketomi A, Shirabe K, Maehara Y and Oda Y:
Tumor-associated macrophage promotes tumor progression via STAT3
signaling in hepatocellular carcinoma. Pathobiology. 80:146–154.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Behboudi S, Boswell S and Williams R:
Cell-mediated immune responses to alpha-fetoprotein and other
antigens in hepatocellular carcinoma. Liver Int. 30:521–526. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yuan JM, Fan Y, Ognjanovic S, Wang R, Van
Den Berg D, Govindarajan S and Yu MC: Genetic polymorphisms of
epidermal growth factor in relation to risk of hepatocellular
carcinoma: two case-control studies. BMC Gastroenterol. 13:322013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liang H, Block TM, Wang M, Nefsky B, Long
R, Hafner J, Mehta AS, Marrero J, Gish R and Norton PA:
Interleukin-6 and oncostatin M are elevated in liver disease in
conjunction with candidate hepatocellular carcinoma biomarker GP73.
Cancer Biomark. 11:161–171. 2012.PubMed/NCBI
|
|
38
|
Cui HD, Qi ZM, Yang LL, Qi L, Zhang N,
Zhang XL, Du SY and Jiang Y: Interleukin-10 receptor expression and
signalling were down-regulated in CD4+ T cells of lupus
nephritis patients. Clin Exp Immunol. 165:163–171. 2011. View Article : Google Scholar
|
